Steven Breazzano
Long/short equity, deep value, contrarian

Taro Pharmaceuticals: Last Week's Move Is Only The Beginning

Taro Pharmaceuticals (NYSE:TARO) is an Israeli-based pharmaceutical company that develops, manufactures, and markets nearly 200 prescription and OTC pharmaceutical products in the US (88% of sales), Canada (8% of sales), and Israel (3% of sales). Although Taro is finally drawing attention in the financial media with its 20%+ move up last week (driven by a Credit Suisse note), the company still flies under the radar and is largely unknown and underfollowed by Wall Street. Taro's impressive record of earnings growth and share price appreciation has largely gone unnoticed. Taro's continued execution combined with the lack of coverage provides room for 50%+ share price appreciation in the coming months as the story unfolds. This upside opportunity is driven by...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details